Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Generali

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
British Journal of Cancer|January 26, 2005
Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclinesA Berruti, R Bitossi, G Gorzegno, et al.
Cancer Treatment Reviews|January 13, 2023
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical reviewF Miglietta, A Fabi, D Generali, et al.
Cancer Treatment Reviews|July 3, 2023
Corrigendum to "Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review" [Cancer Treat. Rev. 114 (2023) 102511]F Miglietta, A Fabi, D Generali, et al.
Cancer Treatment Reviews|May 7, 2023
Corrigendum to "Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review" [Cancer Treatm. Rev. 114 (2023) 102511]F Miglietta, A Fabi, D Generali, et al.
British Journal of Cancer|April 13, 2013
Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancerG Allevi, C Strina, D Andreis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 2016
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)G Jerusalem, G Mariani, E M Ciruelos, et al.
La Clinica Terapeutica|November 23, 2023
Omics sciences and precision medicine in colon cancerG Madeo, G Bonetti, M Gadler, et al.
Breast (Edinburgh, Scotland)|July 19, 2016
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancerD Andreis, S Bonardi, G Allevi, et al.
Breast (Edinburgh, Scotland)|May 4, 2019
Efficacy of extended aromatase inhibitors for hormone-receptor-positive breast cancer: A literature-based meta-analysis of randomized trialsS P Corona, G Roviello, C Strina, et al.
La Clinica Terapeutica|November 23, 2023
Omics sciences and precision medicine in prostate cancerM C Medori, C Micheletti, M Gadler, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
British Journal of Cancer|January 26, 2005
Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclinesA Berruti, R Bitossi, G Gorzegno, et al.
Cancer Treatment Reviews|January 13, 2023
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical reviewF Miglietta, A Fabi, D Generali, et al.
Cancer Treatment Reviews|July 3, 2023
Corrigendum to "Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review" [Cancer Treat. Rev. 114 (2023) 102511]F Miglietta, A Fabi, D Generali, et al.
Cancer Treatment Reviews|May 7, 2023
Corrigendum to "Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review" [Cancer Treatm. Rev. 114 (2023) 102511]F Miglietta, A Fabi, D Generali, et al.
British Journal of Cancer|April 13, 2013
Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancerG Allevi, C Strina, D Andreis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 2016
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)G Jerusalem, G Mariani, E M Ciruelos, et al.
La Clinica Terapeutica|November 23, 2023
Omics sciences and precision medicine in colon cancerG Madeo, G Bonetti, M Gadler, et al.
Breast (Edinburgh, Scotland)|July 19, 2016
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancerD Andreis, S Bonardi, G Allevi, et al.
Breast (Edinburgh, Scotland)|May 4, 2019
Efficacy of extended aromatase inhibitors for hormone-receptor-positive breast cancer: A literature-based meta-analysis of randomized trialsS P Corona, G Roviello, C Strina, et al.
La Clinica Terapeutica|November 23, 2023
Omics sciences and precision medicine in prostate cancerM C Medori, C Micheletti, M Gadler, et al.
Pageof 6